Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine trivalent - GC Pharma

Drug Profile

Influenza virus vaccine trivalent - GC Pharma

Alternative Names: GC 501; GC FLU; GCFlu®; Inactivated, split virion, influenza virus vaccine - GC Pharma; Seasonal influenza virus vaccine - GC Pharma; Trivalent influenza virus vaccine - GC Pharma

Latest Information Update: 07 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 15 Mar 2011 Influenza virus vaccine trivalent (GC FLU®) receives WHO prequalification status for Influenza virus infections (prevention)
  • 01 Jan 2010 Launched for Influenza virus infections in South Korea (IM)
  • 01 Sep 2008 Phase-III clinical trials in Influenza virus infections in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top